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Ion channelWe recently identiﬁed the long non-coding RNA (ncRNA) TRPM2-AS as a key regulator of survival in prostate
cancer [1]. This essential role, coupled to the TRPM2-AS low-expression levels in healthy tissues, makes this
ncRNA a suitable therapeutic target for further clinical studies. To get insights into the survival mechanism con-
trolled by thismolecule, we ablated its expression inprostate cancer cells andperformed a genome-wide analysis
of the transcripts differentially regulated in dying cells. Here, we describe in detail the experimental system,
methods and quality control for the generation of the microarray data associated with our recent publication
[1]. The data are related to [1]. Data have been deposited to the Gene Expression Omnibus (GEO) database repos-
itory with the dataset identiﬁer GSE40687.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).12 V3.0 expression beadchip
normalized data: TXT ﬁles
with TRPM2-AS expression
ression proﬁling to identify
egulated by TRPM2-ASDirect link to the deposited data
Microarray data is deposited at the NCBI Gene Expression Omnibus
(GEO) database under GEO Series and is available at the following
link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40687.
Experimental design, materials and methods
Cell line
The human, androgen-independent prostate cancer cell line PC3was
obtained from ATCC (CRL-1435, ATCC).
Sample source location N/A).
. This is an open access article underRNA interference
During an in-silico search for antisense transcripts [2–4], we have
identiﬁed TRPM2-AS as antisense transcript in respect to TRPM2 gene,
which encodes an oxidative stress-activated ion channel [5]. This long
ncRNA is overexpressed in several tumor types [1,4] and its knock-out
leads to massive apoptosis of PC3 and DU145 prostate cancer cells [1].
To gain a molecular understanding of the mechanisms by which
TRPM2-AS maintains cell survival in prostate cancer cells, PC3 cells
were transfected for 48 h either with a non-speciﬁc siRNA or with a
siRNA ablating TRPM2-AS RNA.
Microarray and quality control
To identify the transcripts that are regulated by TRPM2-AS, we iso-
lated total RNA from four samples (two technical replicates) of PC3
cell lines that had been transfected with the control siRNA or with the
experimental siRNA targeting TRPM2-AS expression. The quantity and
quality of the RNA samples was measured and assessed by a NanoDrop
spectrophotometer and Agilent 2100 Bioanalyzer (Agilent Technolo-
gies). Illumina microarray analysis was performed using the Illumina
HumanHT-12 V3.0 expression beadchip. Quantitative real-time PCR
(qRT-PCR) was used to check the microarray data, analyzing transcript
levels that changed in both directions. In particular segments corre-
sponding to the following transcripts were ampliﬁed: AURKA, PABPC4,
E2F2, CDC20, FRAP1, BIRC5, CDC25B, CDKN1A, IL1B, IL8. Results,the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Validation ofmicroarray data by qRT-PCR. Ten transcripts were quantiﬁed by qRT-PCR both in control and in TRPM2-AS KO PC3 cells. The resulting expression fold change is plotted
against the expression fold change obtained from the Illumina HumanHT-12 V3.0 microarray data. A correlation coefﬁcient of 0.97 was found between the two datasets.
5G. Lavorgna et al. / Genomics Data 3 (2015) 4–5shown in Fig. 1, indicated that while, due to the large dynamic range of
qRT-PCR [6], microarray data were mostly slightly compressed, there
was an excellent qualitative correlation among the two techniques (cor-
relation coefﬁcient: 0.97), thereby validating the microarray
experiment.
Discussion
We report here a dataset composed of microarray gene expression
proﬁling of TRPM2-AS-regulated transcripts. With this experiment,
we were able to show that TRPM2-AS coordinates the expression of a
large number of genes involved in controlling the survival, the unfolded
protein response (UPR) response and the cell-cycle progression in pros-
tate cancer cells. Moreover, targets of existing drugs and treatments
were found to be consistently regulated by TRPM2-AS KO, underlying
the clinical relevance of this long ncRNA as a novel therapeutic target.
According to the dual role of the UPR in promoting cell survival or com-
mitment to programmed cell death [7], several pro-survival molecules
and known oncological targets, including the chaperonin HSP90B1
and the oncogenes FYN and AKT1, were also induced by TRPM2-ASKO, suggesting that the dataset as a whole would be particularly valu-
able for identifying newmolecular targets and underlying mechanisms.
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